Open AccessTime to Viral Rebound After Interruption of Modern Antiretroviral Therapies
Author(s) -
Jonathan Z. Li,
Evgenia Aga,
Ronald J. Bosch,
Mark A. Pilkinton,
Eugène Kroon,
Lynsay MacLaren,
Michael C. Keefer,
Lawrence Fox,
Liz Barr,
Edward P. Acosta,
Jintanat Anaworanich,
Robert W. Coombs,
John W. Mellors,
Alan Landay,
Bernard Macatangay,
Steven G. Deeks,
Rajesh T. Gandhi,
Davey M Smith
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab541
Subject(s) - medicine , viral load , integrase inhibitor , drug holiday , antiretroviral therapy , clinical trial , human immunodeficiency virus (hiv) , protease inhibitor (pharmacology) , immunology
Development of human immunodeficiency virus (HIV) remission strategies requires precise information on time to HIV rebound after treatment interruption, but there is uncertainty regarding whether modern antiretroviral therapy (ART) regimens and timing of ART initiation may affect this outcome.